Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

News SummaryMost relevantAll newsSector newsTweets 

Amgen, Inc. : Amgen 1Q Profit Rises 5.2% On Broad Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
04/24/2012 | 10:40pm CET

Amgen Inc.'s (AMGN) first-quarter earnings rose 5.2% as the biopharmaceutical company reported sales growth across many of its products, helping results beat expectations.

The company has been trying to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its key anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed $1.16 billion acquisition of Micromet Inc. (MITI), a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.18 billion, or $1.48 a share, up from $1.13 billion, or $1.20 a share, a year earlier. Excluding acquisition and restructuring-related expenses and other items, earnings were up at $1.61 from $1.34. Revenue increased 9.2% to $4.05 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.45 on revenue of $3.93 billion.

Operating margin rose to 36.4% from 34.9%.

Combined sales of Neulasta and Neupogen, which are used to ward off infections undergoing cancer treatment, rose 9% to $1.34 billion.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, were up 14% to $153 million. Sales of Prolia, for osteoporosis in women, were up 9% to $153 million.

Shares of Amgen, which affirmed its 2012 guidance, were up 1% to $69.32 in recent after-hours trading.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on AMGEN, INC.
01/17 AMGEN : deCODE Study Shows that Variants in the Sequence of the Genome that Cont..
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/10 AMGEN : Study Results Published in the Journal of the American Medical Associati..
01/10 E THERAPEUTICS : Firm's new chief Drug discovery
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/10 AMGEN : Statement on January 9, 2017, U.S. District Court Decision
01/09 AMGEN, INC. : Blog Coverage Amgen's Legal Victory Blocks Rivals Sanofi and Regen..
01/09 AMGEN INC. (NASDAQ : AMGN) Files An 8-K Entry into a Material Definitive Agreeme..
01/09 AMGEN INC : Entry into a Material Definitive Agreement, Termination of a Materia..
More news
Sector news : Bio Therapeutic Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
01/06DJSanofi Investors Count Cost of Praluent Ruling -- Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
01/18 Most Miller/Howard Rebalanced Winter Dog Dividends Found Safe
01/18 Boehringer Ingelheim's marketing applications for Humira biosimilar under rev..
01/17 Tesoro And Aircastle Are Top Strategic Dividend Index Dogs For Winter
01/17 AnaptysBio Sets Terms For $60 Million IPO
01/17 DGI FOR THE DIY : 2016 Portfolio Review
Financials ($)
Sales 2016 22 776 M
EBIT 2016 11 096 M
Net income 2016 7 776 M
Debt 2016 2 669 M
Yield 2016 2,51%
P/E ratio 2016 15,17
P/E ratio 2017 14,45
EV / Sales 2016 5,21x
EV / Sales 2017 4,95x
Capitalization 115 881 M
More Financials
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Full-screen chart
Technical analysis trends AMGEN, INC.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 182 $
Spread / Average Target 17%
Consensus details
EPS Revisions
More Estimates Revisions
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Chief Financial Officer & Executive Vice President
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Frank J. Biondi Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.6.54%115 159
ACTELION LTD4.58%24 564
More Results